Literature DB >> 9643528

Cancer morbidity in psychiatric patients: influence of lithium carbonate treatment.

Y Cohen1, A Chetrit, Y Cohen1, P Sirota, B Modan.   

Abstract

The relationship between mental diseases and cancer development has been examined in a number of studies but the findings are still inconclusive and suffer from methodological problems. Studies conducted to examine the effect of lithium on malignant cells yielded inconsistent results. The study group included 609 patients treated by lithium carbonate and 2396 controls. A lower but non significant risk (RR = 0.79; CI = 0.17-3.60) to develop non-epithelial tumors was found among lithium carbonate treated psychiatric patients as compared to controls. A significantly (P = 0.05) inverse trend of cancer with lithium dose was observed. The risk of cancer development among each group of psychiatric patients was significantly lower than in the general population (RR = 0.68 for the lithium treated group versus 0.78 for controls). Mental patients have a lower cancer prevalence than the general population and lithium may have a protective effect.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9643528     DOI: 10.1007/bf02787342

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  41 in total

1.  The incidence of cancer in schizophrenic patients.

Authors:  P B Mortensen
Journal:  J Epidemiol Community Health       Date:  1989-03       Impact factor: 3.710

2.  Acute lithium effects on rat brain glucose metabolism - in vivo.

Authors:  P Plenge
Journal:  Int Pharmacopsychiatry       Date:  1976

3.  The enhancement of immunoglobulin synthesis by human lymphocytes with lithium.

Authors:  A P Weetman; A M McGregor; J H Lazarus; B R Smith; R Hall
Journal:  Clin Immunol Immunopathol       Date:  1982-03

4.  Regulatory effect of lithium on thyroxine metabolism in murine neural and anterior pituitary tissue.

Authors:  D L St Germain
Journal:  Endocrinology       Date:  1987-04       Impact factor: 4.736

5.  Lithium inhibits terminal differentiation of erythroleukemia cells. Evidence for a pre-commitment 'priming' event.

Authors:  C Zaricznyj; I G Macara
Journal:  Exp Cell Res       Date:  1987-02       Impact factor: 3.905

6.  Lithium chloride stimulates human monocytes to secrete tumor necrosis factor/cachectin.

Authors:  E S Kleinerman; R D Knowles; M B Blick; L A Zwelling
Journal:  J Leukoc Biol       Date:  1989-11       Impact factor: 4.962

7.  Lithium enhances growth of human leukaemia cells in vitro.

Authors:  C E Gauwerky; D W Golde
Journal:  Br J Haematol       Date:  1982-07       Impact factor: 6.998

Review 8.  Inositol trisphosphate, a novel second messenger in cellular signal transduction.

Authors:  M J Berridge; R F Irvine
Journal:  Nature       Date:  1984 Nov 22-28       Impact factor: 49.962

9.  Development of acute myeloid leukaemia during lithium treatment.

Authors:  J L Nielsen
Journal:  Acta Haematol       Date:  1980       Impact factor: 2.195

10.  Influence of lithium on proliferation of hematopoietic stem cells.

Authors:  V S Gallicchio; M G Chen
Journal:  Exp Hematol       Date:  1981-08       Impact factor: 3.084

View more
  35 in total

1.  Structure determination of glycogen synthase kinase-3 from Leishmania major and comparative inhibitor structure-activity relationships with Trypanosoma brucei GSK-3.

Authors:  Kayode K Ojo; Tracy L Arakaki; Alberto J Napuli; Krishna K Inampudi; Katelyn R Keyloun; Li Zhang; Wim G J Hol; Christophe L M J Verlinde; Ethan A Merritt; Wesley C Van Voorhis
Journal:  Mol Biochem Parasitol       Date:  2010-12-30       Impact factor: 1.759

2.  Regenerating Reputations: Are Wnt and Myc the Good Guys After All?

Authors:  Mark R Frey
Journal:  Dig Dis Sci       Date:  2016-02       Impact factor: 3.199

Review 3.  Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics.

Authors:  Richard S Jope; Christopher J Yuskaitis; Eléonore Beurel
Journal:  Neurochem Res       Date:  2006-08-30       Impact factor: 3.996

Review 4.  Targeting protein kinases in central nervous system disorders.

Authors:  Laura K Chico; Linda J Van Eldik; D Martin Watterson
Journal:  Nat Rev Drug Discov       Date:  2009-11       Impact factor: 84.694

5.  Niche-less maintenance of HSCs by 2i.

Authors:  Shigeo Masuda; Mo Li; Juan Carlos Izpisua Belmonte
Journal:  Cell Res       Date:  2013-01-29       Impact factor: 25.617

6.  Decreased WNT/β-catenin signalling contributes to the pathogenesis of dilated cardiomyopathy caused by mutations in the lamin a/C gene.

Authors:  Caroline Le Dour; Coline Macquart; Fusako Sera; Shunichi Homma; Gisele Bonne; John P Morrow; Howard J Worman; Antoine Muchir
Journal:  Hum Mol Genet       Date:  2017-01-15       Impact factor: 6.150

7.  Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3β and CDK1.

Authors:  Patrick A Mayes; Nathan G Dolloff; Colin J Daniel; J Judy Liu; Lori S Hart; Kageaki Kuribayashi; Joshua E Allen; David I H Jee; Jay F Dorsey; Yingqiu Y Liu; David T Dicker; J Martin Brown; Emma E Furth; Peter S Klein; Rosalie C Sears; Wafik S El-Deiry
Journal:  Cancer Res       Date:  2011-06-06       Impact factor: 12.701

Review 8.  Glycogen synthase kinase-3 as a therapeutic target for cognitive dysfunction in neuropsychiatric disorders.

Authors:  Olivia O'Leary; Yvonne Nolan
Journal:  CNS Drugs       Date:  2015-01       Impact factor: 5.749

Review 9.  Glycogen synthase kinase-3: a potential preventive target for prostate cancer management.

Authors:  Benyi Li; James Brantley Thrasher; Paul Terranova
Journal:  Urol Oncol       Date:  2015-06-04       Impact factor: 3.498

10.  GSK3beta regulates differentiation and growth arrest in glioblastoma.

Authors:  Serdar Korur; Roland M Huber; Balasubramanian Sivasankaran; Michael Petrich; Pier Morin; Brian A Hemmings; Adrian Merlo; Maria Maddalena Lino
Journal:  PLoS One       Date:  2009-10-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.